Skip to content

Trial · Observational

CompletedPhase not statedRegistry data

Vasoactive Intestinal Peptide in COPD

Short name VIPCOPD

NCTNCT00464932 (opens ClinicalTrials.gov in a new tab)Other idEK 168/2003
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase not stated
Enrollment
34 participants
Sponsor
Medical University of Vienna · Other
Design
Not stated
Countries
Not stated
Start
Jun 2003
Primary completion
Not stated
Completion
Jul 2006
First posted
24 Apr 2007 (estimated)
Last update posted
24 Apr 2007 (estimated)
Conditions
COPD · Pulmonary Hypertension

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20032004200520062007
  1. Ph –

    VIPCOPD

    NCT00464932

    Jun 2003 to Jul 2006

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This study, a new immunomodulatory therapy of COPD with vasoactive intestinal peptide (VIP) was evaluated. Based on preliminary unpublished clinical and experimental results, the course of disease under VIP treatment and the molecular mechanisms involved were assessed. 34 patients with severe COPD were treated either with VIP inhalation in addition to conventional therapy or inhalation of placebo plus conventional therapy for a period of 3 months. The trial was conducted as a double blind, comparative study with two parallel groups.

Interventions

  • Vasoactive Intestinal Peptide (VIP)Drug

Arms0

The registry lists no arms for this trial.

Primary outcomes0

Outcomes the sponsor listed as primary.

The registry lists no primary outcome.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 75 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Confirmed moderate to severe COPD with or without pulmonary hypertension * Male and female patients. * Aged 18 - 75 years. * Written consent. * Adequate contraception in female patients of childbearing age. * Negative pregnancy test (four-weekly test repetition). Exclusion Criteria: * Lack of consent * Pregnancy (four-weekly tests) * Lactation * Presumed non-cooperativeness * Patients outside the stipulated age range * Myocardial infarction within the last 12 months * Stroke within the last 12 months * Malignant diseases in anamnesis * Legal incapacity * Parallel participation in a clinical trial * Parallel participation in a clinical trial within the last 4 weeks

PepBank is a research reference. Talk to a doctor before you use any peptide.